244 related articles for article (PubMed ID: 24325739)
1. Side population cell fractions from hepatocellular carcinoma cell lines increased with tumor dedifferentiation, but lack characteristic features of cancer stem cells.
Nakayama M; Ogasawara S; Akiba J; Ueda K; Koura K; Todoroki K; Kinoshita H; Yano H
J Gastroenterol Hepatol; 2014 May; 29(5):1092-101. PubMed ID: 24325739
[TBL] [Abstract][Full Text] [Related]
2. Identification of a unique hepatocellular carcinoma line, Li-7, with CD13(+) cancer stem cells hierarchy and population change upon its differentiation during culture and effects of sorafenib.
Yamada T; Abei M; Danjoh I; Shirota R; Yamashita T; Hyodo I; Nakamura Y
BMC Cancer; 2015 Apr; 15():260. PubMed ID: 25885470
[TBL] [Abstract][Full Text] [Related]
3. Establishment of two distinct human hepatocellular carcinoma cell lines from a single nodule showing clonal dedifferentiation of cancer cells.
Yano H; Iemura A; Fukuda K; Mizoguchi A; Haramaki M; Kojiro M
Hepatology; 1993 Aug; 18(2):320-7. PubMed ID: 8393423
[TBL] [Abstract][Full Text] [Related]
4. Identification and characterization of tumorigenic liver cancer stem/progenitor cells.
Ma S; Chan KW; Hu L; Lee TK; Wo JY; Ng IO; Zheng BJ; Guan XY
Gastroenterology; 2007 Jun; 132(7):2542-56. PubMed ID: 17570225
[TBL] [Abstract][Full Text] [Related]
5. Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma.
Guo Z; Li LQ; Jiang JH; Ou C; Zeng LX; Xiang BD
World J Gastroenterol; 2014 Feb; 20(8):2098-106. PubMed ID: 24616575
[TBL] [Abstract][Full Text] [Related]
6. Identification of Endothelin-1 and NR4A2 as CD133-regulated genes in colon cancer cells.
Puglisi MA; Barba M; Corbi M; Errico MF; Giorda E; Saulnier N; Boninsegna A; Piscaglia AC; Carsetti R; Cittadini A; Gasbarrini A; Sgambato A
J Pathol; 2011 Oct; 225(2):305-14. PubMed ID: 21826669
[TBL] [Abstract][Full Text] [Related]
7. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations.
Ma S; Chan KW; Lee TK; Tang KH; Wo JY; Zheng BJ; Guan XY
Mol Cancer Res; 2008 Jul; 6(7):1146-53. PubMed ID: 18644979
[TBL] [Abstract][Full Text] [Related]
8. Identification of cancer stem cells from human glioblastomas: growth and differentiation capabilities and CD133/prominin-1 expression.
Gambelli F; Sasdelli F; Manini I; Gambarana C; Oliveri G; Miracco C; Sorrentino V
Cell Biol Int; 2012 Jan; 36(1):29-38. PubMed ID: 21916848
[TBL] [Abstract][Full Text] [Related]
9. Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data.
Bahnassy AA; Fawzy M; El-Wakil M; Zekri AR; Abdel-Sayed A; Sheta M
Transl Res; 2015 Mar; 165(3):396-406. PubMed ID: 25168019
[TBL] [Abstract][Full Text] [Related]
10. Isolation and characterization of hepatic cancer cells with stem-like properties from hepatocellular carcinoma.
Tomuleasa C; Soritau O; Rus-Ciuca D; Pop T; Todea D; Mosteanu O; Pintea B; Foris V; Susman S; Kacsó G; Irimie A
J Gastrointestin Liver Dis; 2010 Mar; 19(1):61-7. PubMed ID: 20361077
[TBL] [Abstract][Full Text] [Related]
11. [Progress and prospects in cancer stem cell research for hepatocellular carcinoma].
Xu W; Cao L; Yin ZF
Ai Zheng; 2009 Sep; 28(9):1004-8. PubMed ID: 19728923
[TBL] [Abstract][Full Text] [Related]
12. Biology and clinical implications of CD133(+) liver cancer stem cells.
Ma S
Exp Cell Res; 2013 Jan; 319(2):126-32. PubMed ID: 22999864
[TBL] [Abstract][Full Text] [Related]
13. microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb.
Zhang J; Luo N; Luo Y; Peng Z; Zhang T; Li S
Int J Oncol; 2012 Mar; 40(3):747-56. PubMed ID: 22025269
[TBL] [Abstract][Full Text] [Related]
14. Stemness characteristics of fibrolamellar hepatocellular carcinoma: immunohistochemical analysis with comparisons to conventional hepatocellular carcinoma.
Zenali MJ; Tan D; Li W; Dhingra S; Brown RE
Ann Clin Lab Sci; 2010; 40(2):126-34. PubMed ID: 20421623
[TBL] [Abstract][Full Text] [Related]
15. Investigation of diagnostic utility and expression profiles of stem cell markers (CD133 and CD90) in hepatocellular carcinoma, small cell dysplasia, and cirrhosis.
Yilmaz G; Akyol G; Cakir A; Ilhan M
Pathol Res Pract; 2014 Jul; 210(7):419-25. PubMed ID: 24702884
[TBL] [Abstract][Full Text] [Related]
16. Positive correlation of Oct4 and ABCG2 to chemotherapeutic resistance in CD90(+)CD133(+) liver cancer stem cells.
Jia Q; Zhang X; Deng T; Gao J
Cell Reprogram; 2013 Apr; 15(2):143-50. PubMed ID: 23438193
[TBL] [Abstract][Full Text] [Related]
17. Identification of cancer stem cells from hepatocellular carcinoma cell lines and their related microRNAs.
Xu Y; Xie Y; Wang X; Chen X; Liu Q; Ying M; Zheng Q
Oncol Rep; 2013 Nov; 30(5):2056-62. PubMed ID: 24002436
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal.
Li Y; Jiang F; Liu Q; Shen J; Wang X; Li Z; Zhang J; Lu X
Toxicol Sci; 2015 Jan; 143(1):156-64. PubMed ID: 25304214
[TBL] [Abstract][Full Text] [Related]
19. Ultrasound-targeted microbubble destruction-mediated downregulation of CD133 inhibits epithelial-mesenchymal transition, stemness and migratory ability of liver cancer stem cells.
Liu YM; Li XF; Liu H; Wu XL
Oncol Rep; 2015 Dec; 34(6):2977-86. PubMed ID: 26370320
[TBL] [Abstract][Full Text] [Related]
20. CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Müllerian tumor).
Choijamts B; Jimi S; Kondo T; Naganuma Y; Matsumoto T; Kuroki M; Iwasaki H; Emoto M
Stem Cells; 2011 Oct; 29(10):1485-95. PubMed ID: 21919130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
